Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment.

Holtzheimer PE, Veitengruber J, Wang CC, Krows M, Thiede H, Wald A, Roy-Byrne P.

Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):426-32. doi: 10.1016/j.genhosppsych.2010.02.001. Epub 2010 Apr 2.

2.

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory.

Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, Campbell JV, Garfein RS, Thomas DL, Strathdee SA; STRIVE Project..

J Urban Health. 2004 Jun;81(2):278-90.

3.

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH.

J Clin Psychiatry. 2005 Jan;66(1):41-8.

4.

Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.

Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, Raffa JD, DeVlaming S, Conway B.

Int J Drug Policy. 2007 Oct;18(5):437-43. Epub 2007 Apr 27.

PMID:
17854734
5.

[Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].

Małyszczak K, Inglot M, Pawłowski T, Czarnecki M, Rymer W, Andrzej K.

Psychiatr Pol. 2006 Jul-Aug;40(4):799-808. Polish.

PMID:
17068951
6.

Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients.

Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, Thau K, Fischer G.

Addict Biol. 2009 Apr;14(2):227-37. doi: 10.1111/j.1369-1600.2009.00148.x.

PMID:
19291011
7.

Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.

Reichenberg A, Gorman JM, Dieterich DT.

AIDS. 2005 Oct;19 Suppl 3:S174-8.

PMID:
16251815
8.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
9.
10.

Factor structure and diagnostic efficiency of the BDI-II in treatment-seeking substance users.

Seignourel PJ, Green C, Schmitz JM.

Drug Alcohol Depend. 2008 Mar 1;93(3):271-8.

PMID:
18093749
11.

Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.

Nguyen OK, Dore GJ, Kaldor JM, Hellard ME; ATAHC Protocol Steering Committee..

Int J Drug Policy. 2007 Oct;18(5):447-51. Epub 2007 Feb 21.

PMID:
17854736
12.

What is the best screening test for depression in chronic spinal pain patients?

Choi Y, Mayer TG, Williams MJ, Gatchel RJ.

Spine J. 2014 Jul 1;14(7):1175-82. doi: 10.1016/j.spinee.2013.10.037. Epub 2013 Nov 10.

PMID:
24225008
13.
14.

Validation of diagnostic tests for depressive disorder in drug-resistant mesial temporal lobe epilepsy.

de Lemos Zingano B, Guarnieri R, Diaz AP, Schwarzbold ML, Bicalho MA, Claudino LS, Markowitsch HJ, Wolf P, Lin K, Walz R.

Epilepsy Behav. 2015 Sep;50:61-6. doi: 10.1016/j.yebeh.2015.06.004. Epub 2015 Jun 26.

PMID:
26119622
15.

Screening for depression in diabetes using the Beck Depression Inventory.

Lustman PJ, Clouse RE, Griffith LS, Carney RM, Freedland KE.

Psychosom Med. 1997 Jan-Feb;59(1):24-31.

PMID:
9021863
16.

Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.

Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R.

Am J Gastroenterol. 2011 Dec;106(12):2123-32. doi: 10.1038/ajg.2011.252. Epub 2011 Aug 9.

PMID:
21826113
17.

Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China.

Wang Z, Du J, Zhao M, Page K, Xiao Z, Mandel JS.

Asia Pac Psychiatry. 2013 Sep;5(3):191-6. doi: 10.1111/j.1758-5872.2012.00209.x. Epub 2012 Jul 27.

18.

Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.

Kang HJ, Stewart R, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, Jeong MH, Yoon JS, Kim JM.

Int J Cardiol. 2015;190:114-21. doi: 10.1016/j.ijcard.2015.04.164. Epub 2015 Apr 21.

PMID:
25918060
19.

Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU) : guidelines for clinical practice.

De Bie J, Robaeys G, Buntinx F.

Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):68-80. Review.

PMID:
15832590
20.

Screening for anxiety and depression in dialysis patients: comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory.

Preljevic VT, Østhus TB, Sandvik L, Opjordsmoen S, Nordhus IH, Os I, Dammen T.

J Psychosom Res. 2012 Aug;73(2):139-44. doi: 10.1016/j.jpsychores.2012.04.015. Epub 2012 Jun 11.

PMID:
22789418

Supplemental Content

Support Center